Avibactam
Highest phase reached
Approved
Drug type
Small molecule
First approval year
2015
- First approval year
- 2015
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Avibactam
- Molecular weight
- 265.25
- Structure (SMILES)
- NC(=O)[C@@H]1CC[C@@H]2CN1C(=O)N2OS(=O)(=O)O
- avibactam component of zavicefta
- Avibactam component of zavicefta
- nxl 104
- Nxl-104
- (1R,2S,5R)-7-OXO-6-SULFOOXY-1,6-DIAZABICYCLO(3.2.1)OCTANE-2-CARBOXAMIDE
- 1r 2s 5r 7 oxo 6 sulfooxy 1 6 diazabicyclo 3 2 1 octane 2 carboxamide
- avibactam
- Avibactam
- Avibactam [INN]
- Avibactam [MI]
- Avibactam [USAN]
- Avibactam [WHO-DD]
- avibactam inn
- avibactam mi
- avibactam usan
- avibactam who dd
- nxl 104 free acid
- Nxl-104 free acid
- zavicefta component avibactam
- ZAVICEFTA COMPONENT AVIBACTAM
- CAS registry numbers
- 1192500-31-4
- ChEMBL ID
- CHEMBL1689063
- InChIKey
- NDCUAPJVLWFHHB-UHNVWZDZSA-N
- RxNorm IDs (RxCUI)
- 1603834
- FDA ingredient codes (UNII)
- 7352665165
- 9835049
- 90333665
- Applicant
- ABBVIE
- Approval date
- 7 Feb 2025
- Application number
- NDA217906
- First in class
- No
- Orphan designation
- No
- Availability
- Prescription only
- United States (FDA)
- Approved
- Pharmacology name
- avibactam
- Type
- Synthetic organic
- Drug name stem
- -bactam
- Approval recorded by Guide to Pharmacology
- Yes
Administration routes
- Parenteral
Open Targets mechanisms
- Mechanism
- Bacterial beta-lactamase TEM inhibitor
- Action type
- Inhibitor
- Target
- Beta-lactamase TEM
- Action type
- Inhibitor
- Gene symbol
- ampC
- Protein identifier
- P05364
- Organism
- Enterobacter cloacae
- Action type
- Inhibitor
- Gene symbol
- ampC
- Protein identifier
- P24735
- Organism
- Pseudomonas aeruginosa (strain ATCC 15692 / PAO1 / 1C / PRS 101 / LMG 12228)
- Action type
- Inhibitor
- Gene symbol
- blaUOE-1
- Protein identifier
- Q9EXV5
- Organism
- Escherichia coli
- Condition
- Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Bacterial Infections
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000771
- Subject identifier
- D001424
- Condition
- Urinary Tract Infections
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003103
- Subject identifier
- D014552
- Condition
- Pneumonia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003106
- Subject identifier
- D011014
- Condition
- Pyelonephritis
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001141
- Subject identifier
- D011704
- Condition
- Systemic Inflammatory Response Syndrome
- Highest recorded phase
- 1
- Condition identifier
- EFO:1001478
- Subject identifier
- D018746
- Condition
- Renal Insufficiency
- Highest recorded phase
- 1
- Condition identifier
- HP:0000083
- Subject identifier
- D051437
- Condition
- Gram-Negative Bacterial Infections
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0021678
- Subject identifier
- D016905
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000771
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003103
- Condition identifier
- EFO_0003106
- Condition identifier
- EFO_1001141
- Highest recorded phase
- 3
- Condition identifier
- EFO_1001272
- Condition identifier
- EFO_1001478
- Highest recorded phase
- 1
- Condition identifier
- EFO_1001865
- Highest recorded phase
- 3
- Condition identifier
- HP_0000010
- Condition identifier
- HP_0000083
- Highest recorded phase
- 1
- Condition identifier
- HP_0001945
- Highest recorded phase
- 2
- Condition identifier
- HP_0100806
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0001475
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0003529
- Highest recorded phase
- 3
- Condition identifier
- MONDO_0004652
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0005249
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0006502
- Condition identifier
- MONDO_0021108
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0021678
- Condition identifier
- MONDO_0021678
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0043544
- Condition identifier
- MONDO_0100338
- Highest recorded phase
- 4
Reported adverse events
- Event
- drug resistance
- Reports
- 4
- Reporting signal score
- 18.0572
- NCT01595438
- NCT01599806
- NCT01624246
- NCT01726023
- NCT02475733
- NCT02655419
- NCT04126031
- NCT05258851
- NCT01808092
- NCT02497781
- NCT03580044
- NCT03978091
- NCT04486625
- NCT05639647
- Dose
- 2.67 g
- Route
- Intravenous
- How often
- Every 6 hours
- Hydrogen bond acceptors
- 5
- Hydrogen bond donors
- 2
- Polar surface area
- 130.24
- Calculated partition coefficient (ALogP)
- -1.53
- Calculated partition coefficient (XLogP)
- -1.8
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 17
- Molecular formula
- C7H11N3O6S
- Monoisotopic mass
- 265.03685625
- Natural product
- Yes
- 0074-3878
- Recorded assays
- 254
- Active assays
- 57
Active assay types
- Confirmatory
- beta-Lactamase Inhibitors
Related records
Trials (48)
- A Clinical Study of YK-1169 Versus Ceftazidime-Avibactam in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia
- A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers
- A Study Comparing Ceftazidime-Avibactam Versus Meropenem in Hospitalized Adults With Nosocomial Pneumonia
- A Study of Avycaz (Ceftazidime/Avibactam) Pharmacokinetics/Pharmacodynamics (PK/PD) in Critically Ill Patients
- A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and Separately
- A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects
- A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP
- A Trial to Evaluate the Pharmacokinetics and Safety of AVYCAZ(R) in Combination With Aztreonam
- Aztreonam-Avibactam in Immunocompromised Hosts
- Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
- Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)
- Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens
- Ceftazidime-Avibactam PK/PD and Resistance in Hematology Patients
- Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections
- Clinical Study on Monitoring the Plasma Concentration of Ceftazidime-Avibactam in Critically Ill Patients
- Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections
- Comparing Oral Versus Parenteral Antimicrobial Therapy
- Comparison of Efficacy and Safety of Ceftazidime Avibactam Versus Extended Infusions of High Dose Meropenem in Patients of ACLF With Nosocomial Infections.
- CONTinuous Infusion Versus Intermittent Dosing of ceftaZidime/AVIbactam in Critically Ill Patients
- Different Administration Regimens of CAZ-AVI in Combination With ATM for the Treatment of CR-GNB
Approved for (1)
In development for (9)
- Acute pyelonephritis Phase 3
- Bacterial infectious disease Phase 3
- Gram-negative bacterial infections Phase 2
- Kidney failure Phase 1
- Meningitis Phase 2
- Neutropenia Phase 2
- Pneumonia Phase 3
- Pyelonephritis Phase 3
- Urinary tract infection Phase 2
Other linked conditions (2)
- Acute respiratory distress syndrome
- Nosocomial infection